Biohaven Therapeutics co-led Artizan Biosciences' latest round as part of an option and licensing agreement focusing on its inflammatory bowel disease drug candidates.
Artizan Biosciences, a US-based developer of treatments for inflammatory diseases spun out of Yale University, has collected $11m in a series A2 round co-led by biopharmaceutical company Biohaven Therapeutics. Hatteras Venture Partners co-led the round, which also attracted spinout-focused investment firm Osage University Partners (OUP), Connecticut Innovations and Elm Street Ventures. Artizan is working on…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.